Episode
Daraxonrasib Doubles Pancreatic Cancer Survival
- Published
- Jun 1, 2026
- Duration seconds
- 111
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/toronto-news-today-2-min-news-the-daily-news-now-7593854/episodes/daraxonrasib-doubles-pancreatic-cancer-survival/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/toronto-news-today-2-min-news-the-daily-news-now-7593854/daraxonrasib-doubles-pancreatic-cancer-survival.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A breakthrough drug called daraxonrasib is turning heads in pancreatic cancer treatment, doubling survival time for patients who didn’t respond to chemo. In a major trial, it stopped or reversed tumor growth in nearly a third of patients—far outperforming standard chemo—and pushed median survival from under seven months to around thirteen. Targeting the notorious KRAS mutation, it’s seen as a “game changer” by doctors, offering hope with fewer side effects. Though not yet universally approved, this first-of-its-kind therapy could unlock new treatments for other cancers driven by similar mutations. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/c7b234067ac39e4d